On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
The program offers shipment of free bridge to maintenance supply for commercially insured patients during potential reimbursement delays.
The Resource Center also includes links to the prescription start guide and other patient assistance resources, including comprehensive instructions on how to prepare and submit the prescription as well as the robust support that is available through the Otezla SupportPlus™ program.
For more information, call Otezla SupportPlus™ at 1-844-4OTEZLA (1-844-468-3952)
To receive a free bridge supply of Otezla, commercially insured patients must have an on-label diagnosis and be denied or waiting for coverage. If an in-office Starter Pack (Titration) is not available, please check both the 4-week Starter Pack and Bridge Rx boxes.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations